(Q34884527)

5 August 2017

1 reference

title

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (English)

1 reference

5 August 2017

1 reference

R Hajek

6

0 references

Giampaolo Merlini

G Merlini

3

0 references

Angela Dispenzieri

A Dispenzieri

1

0 references

Athanasios Dimopoulos

M Dimopoulos

International Myeloma Working Group

11

0 references

34

International Myeloma Working Group

1 reference

5 August 2017

32

S V Rajkumar

1 reference

5 August 2017

16

M Gertz

1 reference

5 August 2017

14

B Barlogie

1 reference

5 August 2017

33

B G M Durie

1 reference

5 August 2017

R Kyle

2

1 reference

5 August 2017

J S Miguel

4

1 reference

5 August 2017

H Ludwig

5

1 reference

5 August 2017

A Palumbo

7

1 reference

5 August 2017

S Jagannath

8

1 reference

5 August 2017

J Blade

9

1 reference

5 August 2017

S Lonial

10

1 reference

5 August 2017

R Comenzo

12

1 reference

5 August 2017

H Einsele

13

1 reference

5 August 2017

K Anderson

15

1 reference

5 August 2017

J L Harousseau

17

1 reference

5 August 2017

M Attal

18

1 reference

5 August 2017

P Tosi

19

1 reference

5 August 2017

P Sonneveld

20

1 reference

5 August 2017

M Boccadoro

21

1 reference

5 August 2017

G Morgan

22

1 reference

5 August 2017

P Richardson

23

1 reference

5 August 2017

O Sezer

24

1 reference

5 August 2017

M V Mateos

25

1 reference

5 August 2017

M Cavo

26

1 reference

5 August 2017

D Joshua

27

1 reference

5 August 2017

I Turesson

28

1 reference

5 August 2017

W Chen

29

1 reference

5 August 2017

K Shimizu

30

1 reference

5 August 2017

R Powles

31

1 reference

5 August 2017

20 November 2008

1 reference

5 August 2017

1 reference

5 August 2017

23

1 reference

5 August 2017

2

1 reference

5 August 2017

215-224

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.307

5 August 2017

0 references

cites work

Serum free light chain measurements move to center stage

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum test for assessment of patients with Bence Jones myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Risk of antigen excess in serum free light chain measurements

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum free light chains for monitoring multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Appraisal of immunoglobulin free light chain as a marker of response

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Immunoglobulin free light chains and solitary plasmacytoma of bone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.307

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.307

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference